Xeris Biopharma price to book ratio XERS

Market value divided by the book value of the company's net assets, since 2022.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 107×; Jul 2026
5-year median: 11.6×
5-year range: 2.0× to 117×
Peer median: 2.8×

Xeris Biopharma's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Jul 2026, at 107×.

On the days it had one over the last 5 years, its median was 11.6×, from 2.0× in Jul 2022 to 117× in Jul 2026.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	107×	68.0×	117×
2025	n/m a value too high to mean anything
2024	114×	86.1×	115×
2023	84.0×	2.6×	84.0×
2022	3.3×	2.0×	4.0×

Against its peers

Companies in Drug Manufacturers - General nearest Xeris Biopharma's size, closest first, today.

Company	Price to book ratio
XERSXeris Biopharma	n/m
ANIPANI Pharmaceuticals	2.8×
HRMYHarmony Biosciences	2.1×
PAHCPhibro Animal Health	4.1×
PBHPrestige Consumer Healthcare	1.2×
ANABAnaptysbio	138×
PCRXPacira BioSciences	2.2×
NRIXNurix Therapeutics	2.9×
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	1.4×
OGNOrganon	3.6×
Peer median	2.8×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Xeris Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.